孟德尔随机化揭示尿调节素与血压及慢性肾脏病的因果关系
该研究采用孟德尔随机化方法,在3851人的队列及多个全基因组关联研究汇总数据中,探讨尿调节素(uUMOD)与肾功能、血压的因果关系。结果显示,遗传决定的uUMOD水平升高与eGFR下降、CKD风险增加及血压升高存在因果关联,且对肾功能的影响不通过血压介导。
要点
- 遗传决定的uUMOD升高与eGFR下降和CKD风险增加存在因果关联。
- uUMOD对肾功能的不良影响不通过血压介导。
- uUMOD对血压的影响部分由eGFR介导。
核心结论
- 遗传决定的尿调节素水平对肾功能结局有直接、因果且不利的影响,且不通过血压介导。
研究设计与样本
- 在3851名欧洲裔个体的人群队列中进行单样本孟德尔随机化,并以rs12917707为工具变量。
- 进一步在四个全基因组关联研究汇总数据(CKD 567,460人,血压 757,461人)中进行两样本孟德尔随机化。
主要发现
- 观察性数据中,较高的uUMOD与较高的eGFR相关;但单样本孟德尔随机化显示较高的uUMOD与eGFR下降强烈相关。
- 两样本孟德尔随机化中,uUMOD每升高1个标准差,log转换的eGFR降低0.15 SD(95%CI -0.17至-0.13),CKD的log比值增加0.13 SD(0.12至0.15)。
- uUMOD每升高1个标准差,收缩压升高0.06 SD(0.03至0.09),舒张压升高0.08 SD(0.05至0.12)。
- uUMOD对血压的影响由eGFR介导,而对eGFR的影响不由血压介导。
临床怎么用
- uUMOD可作为肾功能恶化和血压升高的因果生物标志物,但需进一步验证其临床效用。
局限性
- 研究基于欧洲裔人群,结果外推需谨慎。
- 孟德尔随机化依赖工具变量有效性的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UMOD variants associated with higher levels of urinary uromodulin (uUMOD) increase the risk of chronic kidney disease (CKD) and hypertension. However, uUMOD levels also reflect functional kidney tubular mass in observational studies, questioning the causal link between uromodulin production and kidney damage. We used Mendelian randomization to clarify causality between uUMOD levels, kidney function and blood pressure in individuals of European descent. The link between uUMOD and estimated glomerular filtration rate (eGFR) was first investigated in a population-based cohort of 3851 individuals. In observational data, higher uUMOD associated with higher eGFR. Conversely, when using rs12917707 (an UMOD polymorphism) as an instrumental variable in one-sample Mendelian randomization, higher uUMOD strongly associated with eGFR decline. We next applied two-sample Mendelian randomization on four genome wide association study consortia to explore causal links between uUMOD and eGFR, CKD risk (567,460 individuals) and blood pressure (757,461 individuals). Higher uUMOD levels significantly associated with lower eGFR, higher odds for eGFR decline or CKD, and higher systolic or diastolic blood pressure. Each one standard deviation (SD) increase of uUMOD decreased log-transformed eGFR by -0.15 SD (95% confidence interval -0.17 to -0.13) and increased log-odds CKD by 0.13 SD (0.12 to 0.15). One SD increase of uUMOD increased systolic blood pressure by 0.06 SD (0.03 to 0.09) and diastolic blood pressure by 0.08 SD (0.05 to 0.12). The effect of uUMOD on blood pressure was mediated by eGFR, whereas the effect on eGFR was not mediated by blood pressure. Thus, our data support that genetically driven levels of uromodulin have a direct, causal and adverse effect on kidney function outcome in the general population, not mediated by blood pressure.
引用
- Ponte B, Sadler MC, Olinger E, et al. Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease. Kidney Int. 2021. PMID: 34634361. doi:10.1016/j.kint.2021.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。